• UVM Cancer Center, Larner College of Medicine 

• Dartmouth Cancer Center

• UVM Cancer Center

• Beth Israel Lahey Health Exeter

https://asco.quorum.us/campaign/56411/

Enjoy this wonderful interview with 3 of NNECOS' founding members!

Latest FDA Approval

• March 19 - FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
• February 14 - FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor
• February 11 - FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma
• February 11 - FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
• January 27 - FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer
• January 21 - FDA approves treosulfan with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation
• January 17 - FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
• January 16 - FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma
• January 16 - FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer
• December 27 - FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
• December 20 - FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation
• December 18 - FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer
• December 18 - FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients

• December 13 - FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma

• December 4 - FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma
• November 20 - FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer
• November 19 - FDA approves updated drug labeling for fludarabine phosphate under Project Renewal
• November 15 - FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation
• November 8 - FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
• October 29 - FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia
• October 18 - FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma
• October 10 - FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
• October 3 - FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer

Package/Label Updates

Code Updates

• Claim Issue Reported 1/8/25 impacting Part B providers in Jurisdiction JK and Jurisdiction J6 - Claims with healthcare common procedure coding system (HCPCS) G2211 with date of service (DOS) 1/1/2024-9/30/2024.

• Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
  

Other Updates